- Home
- ELVN vs MFA Comparison
ELVN vs MFA Comparison
Compare ELVN & MFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELVN | MFA |
|---|---|---|
| Founded | 2016 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 976.0M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ELVN | MFA |
|---|---|---|
| Price | $15.48 | $9.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $41.00 | $10.96 |
| AVG Volume (30 Days) | 799.2K | ★ 1.3M |
| Earning Date | 11-12-2025 | 02-18-2026 |
| Dividend Yield | N/A | ★ 15.25% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.86 |
| Revenue | N/A | ★ $279,011,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.18 |
| P/E Ratio | ★ N/A | $10.98 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.30 | $7.85 |
| 52 Week High | $25.08 | $11.08 |
Technical Indicators
Market Signals| Indicator | ELVN | MFA |
|---|---|---|
| Relative Strength Index (RSI) | 35.13 | 44.51 |
| Support Level | $14.79 | $9.32 |
| Resistance Level | $18.05 | $9.52 |
| Average True Range (ATR) | 0.90 | 0.17 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 17.30 | 20.80 |
Price Performance
Historical ComparisonAbout ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About MFA MFA Financial Inc.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.